# Study of the Orsiro Drug Eluting Stent System

Study · id `cardio:ct-nct01356888` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01356888](<https://clinicaltrials.gov/study/NCT01356888>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01356888

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 452 participants.

## Technical summary

Registry record NCT01356888. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 452 participants (enrolled count; ClinicalTrials.gov record NCT01356888, source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01356888, source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01356888, source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)
- Completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT01356888, source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)
- Countries: Austria; France; Germany; Hungary; Latvia; Netherlands; Spain; Switzerland (ClinicalTrials.gov record NCT01356888, source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01356888-2018-05-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Orsiro Drug Eluting Stent System
- Acronym: BIOFLOW-II
- Condition: Coronary Artery Disease
- Intervention (Device): Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)
- Intervention (Device): Percutaneous Coronary Intervention (Orsiro DES)
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial (`cardio:pubmed-29798778`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial (`cardio:pubmed-25634905`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4ddb7d9632d938f2978e6ad33a08eb7fb3d535db3b33ff2b9163e010847aeef1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
